Arkolith/Insider Trading/ARTH/Form 4

Abrams Michael S

CHIEF FINANCIAL OFFICERArch Therapeutics, Inc. (ARTH) · full profile →Form 4 · filed Sep 8, 2023
Net Buying
Open-Market Buys
$3K
Open-Market Sells
$0
Net Open-Market Flow
$3K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 31, 2023Buy(P)10K$0.28$3K10K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 31, 2023Grant(A)21K——21K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-23-025515) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML